This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| North American Brain Tumor Consortium | |
|---|---|
| Name | North American Brain Tumor Consortium |
| Formation | 1990s |
| Type | Research consortium |
| Headquarters | United States |
| Region served | North America |
| Leader title | Director |
North American Brain Tumor Consortium is a multi-institutional clinical research consortium focused on neuro-oncology that coordinates early-phase clinical trials and translational research for primary and metastatic brain tumors. It connects academic medical centers, cancer centers, pharmaceutical companies, regulatory agencies and patient advocacy groups to accelerate therapeutic development for glioma, medulloblastoma and other central nervous system neoplasms. The consortium operates within a landscape that includes major institutions and initiatives across United States, Canada, the National Institutes of Health, the Food and Drug Administration, and international research networks.
The consortium was established in the 1990s to respond to unmet needs identified by investigators at institutions such as Johns Hopkins University, Massachusetts General Hospital, Mayo Clinic, University of California, San Francisco, and University of Pennsylvania. Early activities intersected with efforts at the National Cancer Institute, collaborations with the Radiation Therapy Oncology Group and interactions with foundations like the American Brain Tumor Association and National Brain Tumor Society. Its evolution paralleled developments at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Stanford University School of Medicine, and international centers including University of Toronto and McGill University. Over time the consortium adapted to regulatory frameworks shaped by the Food and Drug Administration Modernization Act, harmonized protocols influenced by the International Conference on Harmonisation, and trial designs popularized by groups such as EORTC and Children's Oncology Group.
The consortium’s mission aligns with priorities articulated by the National Cancer Institute and advocacy from organizations like the Michael J. Fox Foundation and Susan G. Komen Foundation in expanding targeted therapeutics, biomarkers, and precision medicine approaches. Objectives include accelerating phase I and II studies in collaboration with pharmaceutical partners such as Novartis, Pfizer, Roche, Merck & Co., and biotechnology firms, while integrating insights from research at Cold Spring Harbor Laboratory, Broad Institute, and Salk Institute. It aims to translate discoveries from laboratories at institutions like Harvard Medical School, Yale School of Medicine, and Columbia University Irving Medical Center into trials that leverage molecular profiling tools developed at Stanford University and University of California, San Diego.
Governance typically involves principal investigators drawn from centers including Cleveland Clinic, University of Michigan, Duke University School of Medicine, Northwestern University, and University of Pittsburgh Medical Center. Steering committees coordinate with protocol chairs, data safety monitoring boards with members from Johns Hopkins Bloomberg School of Public Health and Columbia University, and biostatistics teams influenced by methods used at the Fred Hutchinson Cancer Research Center and University of Washington. Administrative cores interact with contracting offices at Boston Children’s Hospital and regulatory liaisons familiar with European Medicines Agency and Health Canada processes. Patient-representative advisory councils often include advocates associated with American Cancer Society and survivor networks.
The consortium designs early-phase interventional trials for glioblastoma, anaplastic astrocytoma, meningioma, and brain metastases, drawing on molecular taxonomy efforts from The Cancer Genome Atlas and epigenetic profiling work by researchers at Cold Spring Harbor Laboratory and Salk Institute. Trials have tested targeted agents, immunotherapies, oncolytic viruses, and novel delivery methods investigated at laboratories such as Johns Hopkins University and Stanford University School of Medicine. Protocols incorporate imaging endpoints from centers like Mayo Clinic and biomarker assays developed with collaborators at the Broad Institute and Dana-Farber Cancer Institute. The consortium has run multicenter phase I/II studies that align with trial designs used by National Cancer Institute-sponsored networks and cooperative groups such as Alliance for Clinical Trials in Oncology.
Partnerships span academic medical centers, industry sponsors including Amgen, AstraZeneca, Bristol Myers Squibb, and regulatory stakeholders like the Food and Drug Administration and Health Canada. Collaborative networks include linkages to the European Organisation for Research and Treatment of Cancer and pediatric research groups like the Pediatric Brain Tumor Consortium. The consortium works with foundations such as the American Brain Tumor Association, National Brain Tumor Society, and patient advocacy organizations that coordinate with international charities like Brain Tumour Charity to support trial enrollment and outreach.
Funding sources combine grants from the National Institutes of Health, cooperative agreements with the National Cancer Institute, industry-sponsored trial support from multinational firms, and philanthropic contributions from entities similar to the Robert Wood Johnson Foundation and private donors associated with centers like Memorial Sloan Kettering Cancer Center. Oversight involves institutional review boards at participating hospitals, data safety monitoring boards influenced by standards from the World Health Organization and compliance with regulations from Health Canada and the Food and Drug Administration.
Consortium trials have contributed to understanding drug penetration of the blood–brain barrier, helped validate molecular targets identified by The Cancer Genome Atlas and studies at Broad Institute, and informed subsequent randomized trials at networks including the Radiation Therapy Oncology Group and Alliance for Clinical Trials in Oncology. Publications authored by investigators affiliated with Johns Hopkins University, Dana-Farber Cancer Institute, University of California, San Francisco, and Stanford University have influenced clinical practice guidelines used by centers such as Mayo Clinic and Cleveland Clinic. Outcomes include characterization of safety profiles for novel agents, identification of predictive biomarkers, and facilitation of regulatory submissions to bodies like the Food and Drug Administration.
Category:Medical research organizations